USPTO Patent Application for CsgA-Derived Nanostructures for Antigen Delivery

ChangeBridge: Patent Apps - Peptides (C07K)

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083834A1) for CsgA-derived nanostructures designed for antigen delivery. The application details self-assembling polypeptides conjugated to immunogens that form nanofilaments to stimulate immune responses, potentially for vaccines against various conditions.

View original document View source feed page

What changed

This document is a publication of a United States Patent Application (US20260083834A1) filed by inventors Steve Bourgault et al. The application describes novel self-assembling polypeptides derived from the CsgA protein, which can be conjugated to immunogens. These conjugates self-assemble into nanofilaments capable of activating humoral and cellular immune responses, with potential applications in vaccines for preventing or treating microbial infections, cancer, autoimmune diseases, and allergies.

This is a patent application, not a regulatory rule or enforcement action. It does not impose new compliance obligations on regulated entities. However, it is relevant for pharmaceutical and biotechnology companies involved in vaccine development and antigen delivery systems. Companies in this space may wish to review the application for potential intellectual property insights or competitive intelligence regarding novel approaches to immune response stimulation.

Source document (simplified)

← USPTO Patent Applications

CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY

Application US20260083834A1 Kind: A1 Mar 26, 2026

Inventors

Steve BOURGAULT, Denis ARCHAMBAULT, Dominic ARPIN, Felix LAMONTAGNE

Abstract

Purified antigens are usually weakly immunogenic and require the addition of immunostimulatory agents and/or delivery systems to generate robust antigen-specific responses. The present application relates to self-assembling polypeptides that may be conjugated to immunogens and have the ability to self-assemble into immunogen-displaying nanofilaments that activate the humoral and cellular immune responses. The self-assembling polypeptide comprises an amino acid sequence having at least 60% identity with the sequence of the R4 and R5 domains from a Curli-specific gene A (CsgA) protein. The present application also relates to nucleic acids encoding the self-assembling polypeptide/immunogen conjugates, to compositions and vaccines comprising the self-assembling polypeptide/immunogen conjugates or nucleic acids, as well as to methods for inducing an immune response against an immunogen and/or for preventing and/or treating a microbial infection, cancer or any pathological conditions in which vaccination may be useful such as autoimmune diseases and allergies, in a subject.